==== Front J Fungi (Basel) J Fungi (Basel) jof Journal of Fungi 2309-608X MDPI 33019741 10.3390/jof6040202 jof-06-00202 Article Prevalence of Vitamin D Deficiency in Treatment-Naïve Subjects with Chronic Pulmonary Aspergillosis Sehgal Inderpaul Singh 1 Dhooria Sahajal 1 Prasad Kuruswamy Thurai 1 Muthu Valliappan 1 Sachdeva Naresh 2 Bhadada Sanjay Kumar 2 Aggarwal Ashutosh Nath 1 Garg Mandeep 3 https://orcid.org/0000-0003-1555-3807Chakrabarti Arunaloke 4 https://orcid.org/0000-0003-2547-7668Agarwal Ritesh 1* 1 Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India; inderpgi@outlook.com (I.S.S.); sahajal@gmail.com (S.D.); docktp@gmail.com (K.T.P.); valliappa@gmail.com (V.M.); aggarwal.ashutosh@outlook.com (A.N.A.) 2 Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India; naresh_pgi@hotmail.com (N.S.); bhadadask@rediffmail.com (S.K.B.) 3 Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India; gargmandeep@hotmail.com 4 Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India; arunaloke@hotmail.com * Correspondence: agarwal.ritesh@outlook.in; Tel.: +91-172-2756825; Fax: +91-172-2748215 01 10 2020 12 2020 6 4 20210 8 2020 15 9 2020 © 2020 by the authors.2020Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).The association of vitamin D deficiency in the pathogenesis of invasive and allergic pulmonary aspergillosis is known. Whether vitamin D deficiency is prevalent in chronic pulmonary aspergillosis (CPA) remains unknown. We evaluated the prevalence of vitamin D deficiency in subjects with CPA. We compared the clinicoradiological features, microbiology, the immunological response, and the severity of CPA in those with or without vitamin D deficiency. We measured plasma vitamin D levels in 230 consecutive treatment-naïve subjects with CPA and 78 controls (28 with prior tuberculosis (TB); 50 healthy controls). We defined vitamin D deficiency as 25(OH)D3 level <20 ng/mL. The mean (95% confidence intervals (CI)) levels of plasma vitamin D levels were 19.5 (17.6–21.4), 18.6 (13.9–23.3), and 15.3 (12.6–17.9) ng/mL in subjects with CPA, diseased controls, and healthy controls, respectively; and the levels were not different between the groups. The prevalence of vitamin D deficiency in subjects with CPA was 65% (n = 150) and was also not different between healthy (70%) or diseased (61%) controls. We did not find any difference in the clinicoradiological features, microbiology, immunological response, and severity of CPA between vitamin D sufficient and deficient groups. The prevalence of vitamin D deficiency is high in subjects with CPA, albeit similar to controls. Vitamin D deficiency does not affect the disease severity in subjects with CPA. chronic pulmonary aspergillosis (CPA)aspergillosisImmunoCapELISAaspergilloma ==== Body 1. Introduction The fungus Aspergillus causes a spectrum of diseases in humans, depending on the host immunity. In those with structural lung disorders, Aspergillus causes chronic infection, namely chronic pulmonary aspergillosis (CPA) [1]. CPA can be categorized as simple aspergilloma (SA), chronic cavitary pulmonary aspergillosis (CCPA; presence of one or more cavities with or without a fungal ball), chronic fibrosing pulmonary aspergillosis (cavitation and fibrosis involving two or more lobes), and Aspergillus nodule [2,3]. CPA is believed to occur secondary to defects in lung immune responses that result in the ineffective clearing of the fungi [4,5,6]. Vitamin D, a non-essential vitamin primarily involved in bone metabolism, has also been demonstrated to have immunomodulatory effects by enhancing innate and adaptive immunity [7,8]. Vitamin D modulates the Th1, Th2, and Th17 immune responses [9], and upregulates the regulatory T cells [7,10]. Vitamin D also promotes the clearance of Aspergillus [8,10]. Whether vitamin D deficiency is associated with CPA or its severity is not known. We hypothesized that subjects with CPA would have a high prevalence of vitamin D deficiency and that those with a deficiency are likely to have a severe disease. Herein, we determine the prevalence of vitamin D deficiency in subjects with CPA. We also compare the clinical, radiological, immunological, and microbiological characteristics in subjects with CPA of those with or without vitamin D deficiency. 2. Materials and Methods This was a case-control study conducted between January 2019 and April 2020 in the Chest Clinic of this Institute. The Institute Ethics Committee (NK/4394/Res/512; 4th May 2018) approved the study protocol, and written informed consent was obtained from all the study participants. We have previously published some of the data [11,12]. 2.1. Study Participants Cases: We included consecutive treatment-naïve subjects with CPA (Supplementary Table S1). Briefly, the presence of all of the following was used to diagnose CPA: (1) respiratory symptoms for at least three months; (2) radiological features of a cavity with or without a fungal ball or pleural thickening or pericavitary infiltrates or nodules on a computed tomography (CT) of the thorax; (3) demonstration of Aspergillus infection by either culture or serological methods; and (4) exclusion of other pulmonary disorders with a similar presentation [2,3,11,13]. We excluded subjects with any of the following: (1) failure to provide informed consent; (2) intake of antifungal azoles for >3 weeks in the preceding six months; and (3) pregnancy. We performed a sputum or bronchoalveolar lavage fluid (BALF) smear for acid-fast bacilli, Xpert MTB/Rif, and culture for mycobacteria and bacterial pathogens to exclude other pulmonary infections. Controls: The disease controls were subjects with previously treated pulmonary tuberculosis who had minimal symptoms or radiological abnormalities and did not fulfill the criteria for CPA. We also included 50 healthy controls. The healthy controls were the health care workers (technicians, nurses, doctors) working in the same hospital, including some of the authors of the manuscript. None of the healthy controls reported any comorbid illness and all had a normal body mass index (BMI). Study objective: The primary outcome was to evaluate the prevalence of vitamin D deficiency in subjects with CPA. The secondary objectives were to compare the clinical, immunological, microbiological profile and the severity of CPA in those with or without vitamin D deficiency. For the study, we categorized CPA as severe if there were two or more cavities on the CT thorax or a single cavity with serum A. fumigatus-specific IgG >100 mg A/L. 2.2. Study Procedure We performed the following investigations in the study population: serum A. fumigatus-specific IgE and IgG levels, serum total IgE, sputum culture for fungus, mycobacteria, and bacteria, complete blood count, C-reactive protein values, estimation of galactomannan in serum and BALF, spirometry, chest radiograph, CT of the thorax, and vitamin D levels. We evaluated the quality of life in cases and diseased controls using the St. George’s Respiratory Questionnaire [14]. Serum A. fumigatus-specific IgE and IgG levels: We assayed A. fumigatus-specific IgE and IgG using the automated fluorescent enzyme immunoassay (Phadia 100, Thermofisher Scientific, Uppsala, Sweden) [11,15]. An A. fumigatus-specific IgE and IgG value >0.35 kUA/L and >27 mgA/L, respectively, was considered positive [11,15]. Serum total IgE levels: We estimated the serum total IgE using the fluorescent enzyme immunoassay system (Phadia 100, Thermo Fisher Scientific, Uppsala, Sweden) [16]. Serum and BALF galactomannan: We measured the serum and BALF GM using a one-stage immune-enzymatic sandwich microplate assay (Platelia Aspergillus EIA; Bio-Rad Laboratories, Hercules, CA, USA), according to the manufacturer’s recommendations. We used the serum and BALF cut-off values of >0.6 and >1.6, respectively, to diagnose CPA [2,12,15]. Sputum and BALF fungal cultures: We used the respiratory samples treated with N-acetyl-l-cysteine (NALC) and sodium citrate for microscopy (calcofluor dye with potassium hydroxide) and culture (Sabouraud glucose agar medium). We identified Aspergillus species cultured on malt extract agar and Czapek–Dox agar by their morphological characteristics. Vitamin D levels: We estimated the total plasma 25-hydroxyvitamin D levels by a competitive electrochemiluminescence immunoassay on a fully automated analyzer (E601, Roche Diagnostics GmbH, Mannheim, Germany). The minimum detection limit of the assay was 3 ng/mL. The inter- and intra-assay coefficient of variation was 13.1% and 6.8%, respectively. We defined vitamin D (25[OH]D3) levels ≥30 ng/mL, 21–29 ng/mL, and <20 ng/mL as normal, insufficient, and deficient, respectively [9,17]. 2.3. Statistical Analysis Data are presented descriptively as a mean (95% confidence interval (95% CI)) or number (percentage). We analyzed the difference between continuous and categorical variables using the Mann–Whitney U test and Fischer’s exact test, respectively. A p-value <0.05 was considered statistically significant. 3. Results We included 230 cases with CPA and 78 controls (28 with prior TB; 50 healthy controls). The demographic profile was similar in cases and controls (Table 1). The diseased controls were minimally symptomatic and had the same duration of symptoms compared to CPA. Subjects with CPA were more likely to have a cough and recurrent hemoptysis when compared to diseased controls. The quality of life assessed by the SGRQ questionnaire was poor in subjects with CPA. The symptom and the activity domains were the most affected in subjects with CPA. The serum A. fumigatus-specific IgG levels were significantly higher in subjects with CPA compared to the diseased controls. There were no significant differences in the serum GM levels or other immunological parameters between CPA and diseased controls. One or more cavities on the CT thorax were universal in subjects with CPA (Table 1). Primary outcome: The mean (95% CI) serum vitamin D level was 19.5 (17.6–21.4) ng/mL in subjects with CPA. There was no statistically significant difference in vitamin D levels among cases and controls (Table 2). The prevalence of vitamin D deficiency was 65% (n = 150) in subjects with CPA, like healthy (70%) and diseased (61%) controls. Secondary outcomes: Subjects with vitamin D deficiency were significantly younger than the nondeficient group (Table 3). We did not observe any difference in the clinical parameters, pulmonary function, inflammatory markers (ESR, CRP), and quality of life in subjects with CPA with or without vitamin D deficiency. We also did not observe any difference in the immunological findings (A. fumigatus-specific IgE and IgG, serum total IgE), serum and BALF GM, and demonstration of Aspergillus in respiratory secretions in subjects with or without vitamin D deficiency. There was no difference in the underlying etiology for CPA (TB vs. non-TB), the radiological findings of the CT thorax, or the type of CPA in subjects with or without vitamin D deficiency. Importantly, vitamin D deficiency was not associated with the severity of CPA. 4. Discussion We found a high prevalence of vitamin D deficiency in subjects with CPA. However, the prevalence of vitamin D deficiency was not different between diseased and healthy controls. We also found no difference in the quality of life, lung function, immunological profile, or severity of disease in subjects of CPA with or without vitamin D deficiency. After inhalation, the Aspergillus conidia are effectively cleared by the body’s immune system by innate and adaptive immune responses [4,6]. Both genetic and acquired defects in the production of interleukin (IL-10), IL-12, IL-17, interferon–gamma (IFN-γ), mannose-binding lectin (MBL), toll-like receptors (TLR), and transforming growth factor–beta (TGF-β) have been implicated in CPA [18]. Vitamin D plays a vital role in immunity against infections with Aspergillus by enhancing the proliferation of TGF-β, producing regulatory T-cells, by an improved phagocytic activity of macrophages, and by a cathelicidin-induced enhancement in the innate immune functions of the alveolar epithelial cells [7,8,19]. Besides, vitamin D increases resistance against Aspergillus infection by modulating autophagy [20]. Vitamin D inhibits the formation and release of Th1 cytokines whilst inducing the Th2 cytokines [21,22]. We were also anticipating that subjects of CPA with vitamin D deficiency would demonstrate an increase in A. fumigatus-specific IgG levels compared to those without. However, we did not find any difference in the immunological response, severity of CPA, or quality of life in relation to vitamin D levels. While a few studies have demonstrated a prevalence of vitamin D deficiency in allergic aspergillosis [9,23], none have evaluated the association between vitamin D deficiency and CPA. We found a high prevalence (65%) of vitamin D deficiency in subjects with CPA. The most common underlying structural lung disease in our study was the sequelae of pulmonary tuberculosis. Although vitamin D deficiency also increases the risk of tuberculosis [24,25], the prevalence of vitamin D deficiency in our study did not vary depending on the underlying etiology for CPA (TB vs. non-TB). The high prevalence of vitamin D deficiency is likely due to a high prevalence of vitamin D deficiency, in general, in the Indian population [26]. It is possible that the vitamin D cut-off for deficiency is likely to be different in the Indian population; however, the cut-off currently remains unclear. This is the reason why we chose the 20 ng/mL mark for deficiency. What are the clinical implications of this study? We found a high prevalence of vitamin D deficiency in treatment-naïve subjects with CPA, irrespective of the underlying etiology for CPA. While vitamin D deficiency was not associated with the severity of CPA, the question of whether a replacement of vitamin D in deficient subjects improves treatment outcomes in CPA should be ascertained in future studies. Finally, our research has a few limitations, the major one being that it comprised a report from a single center. More studies from different geographic locales are needed to ascertain the prevalence of vitamin D deficiency in CPA. We also do not have follow-up details regarding treatment outcomes with antifungal agents in those with or without vitamin D deficiency. Finally, we used a convenient sample size for the study. Assuming a prevalence of vitamin D deficiency of 70% in control and 80% in CPA, with a two-sided confidence level (1-alpha) of 95% and power of 80%, we would require 600 subjects (300 cases and 300 controls). In conclusion, there was a high prevalence of vitamin D deficiency in subjects with CPA, although it was comparable to subjects without CPA. Vitamin D deficiency was also not associated with the severity of CPA. Supplementary Materials The following are available online at https://www.mdpi.com/2309-608X/6/4/202/s1. Table S1: Diagnostic criteria for diagnosis of chronic pulmonary aspergillosis. Click here for additional data file. Author Contributions Conceptualization, R.A. and I.S.S.; methodology, I.S.S., R.A.; formal analysis, I.S.S.; investigation, I.S.S., S.D., K.T.P., V.M., N.S., S.K.B., A.N.A., M.G., A.C., R.A.; data curation, I.S.S., R.A.; writing—original draft preparation, I.S.S.; writing—review and editing, I.S.S., S.D., K.T.P., V.M., N.S., S.K.B., A.N.A., M.G., A.C., R.A. All authors have read and agreed to the published version of the manuscript. Funding This research received no external funding. Conflicts of Interest The authors declare no conflict of interest. jof-06-00202-t001_Table 1Table 1 Demographics and clinical profile of the study population. Parameter CPA (n = 230) Diseased Controls (n = 28) Healthy Controls (n = 50) p-Value Demographic Age, years 43.9 (42–45.7) 47 (40.3–53.7) 41.1 (37.2–45.1) 0.23 Male sex 117 (50.9) 19 (67.9) 29 (58) 0.19 BMI, kg/m2 19.6 (19–20.2) 21.2 (19.4–23) - 0.08 Clinical findings Duration of symptoms, years 1.9 (1.5–2.4) 1.2 (0.5–1.8) 0.26 Cough 200 (87) 19 (67.9) 0.02 Dyspnea 52 (23.4) 4 (14.3) 0.34 Recurrent hemoptysis 156 (68.1) 8 (28.6) <0.0001 Spirometry FEV1, liters 1.78 (1.54–2.03) 1.38 (1.13–1.63) - 0.24 FVC, liters 2.24 (2.11–2.36) 2.13 (1.86–2.39) - 0.54 FEV1/FVC ratio 72.8 (70.6–75.1) 63.7 (57.8–69.5) - 0.006 ESR 31.4 (27.5–35.4) 33.5 (1.9–65.1) - 0.85 Quality of life (SGRQ) Total score 22.5 (20.6–24.4) 16.6 (11.2–22) - 0.05 Symptom domain 33.9 (32.1–35.7) 27.5 (21.9–33.1) - 0.03 Activity domain 30.5 (27.7–33.3) 21.9 (13.7–30) - 0.04 Impact domain 14.2 (11.9–16.6) 9.9 (4.6–15.2) - 0.23 Immunological findings A. fumigatus-specific IgG, mgA/L 100.3 (92.4–108.3) 12.8 (10.3–15.4) - <0.0001 A. fumigatus-specific IgE, kUA/L 1.5 (0.9–2) 0.3 (0.1–0.8) - 0.12 Serum Total IgE levels, IU/mL 714 (533–897) 423 (226–619) - 0.27 Peripheral blood eosinophil count, µL 259 (230–288) 207 (140–275) - 0.23 Serum galactomannan, ODI 0.77 (0.6–0.95) 0.39 (0.28–0.51) - 0.13 BALF galactomannan, ODI 3.7 (3.1–4.3) - - - CT thorax findings Presence of cavity on CT thorax 230 (100) 12 (42.9) - <0.0001 Parenchymal fibrosis 179 (78.2) 23 (82.1) - 0.81 All values are represented as a mean (95% confidence intervals) or number (percentage), unless stated; BALF: bronchoalveolar lavage fluid; BMI: body mass index; CPA: chronic pulmonary aspergillosis; CT: computed tomography; ESR erythrocyte sedimentation rate; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; ODI: optical density index; SGRQ: St George’s respiratory questionnaire. jof-06-00202-t002_Table 2Table 2 Vitamin D characteristics in the study population. CPA (230) Diseased Controls (n = 28) Healthy Controls (50) p–Value Vitamin D levels, ng/mL 19.5 (17.6–21.4) 18.6 (13.9–23.3) 15.3 (12.6–17.9) 0.13 Vitamin D status, n (%) 0.67 Normal 36 (15.7) 5 (17.9) 4 (8) Vitamin D insufficiency 44 (19.1) 6 (21.4) 11 (22) Vitamin D deficiency 150 (65.2) 17 (60.7) 35 (70) All values are represented as a mean (95% confidence intervals) or number (percentage), unless stated. jof-06-00202-t003_Table 3Table 3 Demographics and clinical profile of subjects with CPA with or without vitamin D deficiency (<20 ng/mL). Parameter Vitamin D Deficient (n = 150) Vitamin D Nondeficient (n = 80) p-Value Demographic Age, years 41 (39–43) 49 (46–52) <0.0001 Male gender 71 (57.5) 46 (47.3) 0.09 BMI, kg/m2 19.5 (18.8–20.2) 19.8 (18.9–20.8) 0.61 Clinical findings Duration of symptoms, years 1.8 (1.4–2.3) 2.1 (1.2–3) 0.55 Cough 129 (86) 71 (88.8) 0.68 Dyspnea 36 (24.5) 16 (21.3) 0.74 Recurrent hemoptysis 101 (67.3) 55 (69.8) 0.77 Malaise 24 (16.1) 18 (22.5) 0.28 Spirometry FEV1, liters 1.85 (1.48–2.22) 1.66 (1.47–1.86) 0.49 FVC, liters 2.23 (2.08–2.37) 2.24 (2.01–2.48) 0.89 Inflammatory markers ESR 29.6 (25–34) 34.9 (27–42.8) 0.21 CRP 30 (17–43) 13 (5–21) 0.09 Quality of life (SGRQ) Total score 23.6 (21–26) 20.6 (17.6–23.5) 0.14 Symptom domain 33.7 (31–36) 34.2 (31–37.2) 0.79 Activity domain 32 (28–35.6) 12.6 (9–16) 0.18 Impact domain 15 (12–18) 9.9 (4.6–15.2) 0.30 Immunological findings A. fumigatus-specific IgG, mgA/L 101.1 (90.9–111.3) 98.9 (86.2–111.7) 0.80 A. fumigatus-specific IgE, kUA/L 1.8 (1.1–2.6) 0.9 (0.4–1.4) 0.10 Serum Total IgE levels, IU/mL 819 (568–1070) 517 (293–741) 0.12 Serum galactomannan, ODI 0.77 (0.6–0.95) 0.77 (0.42–1.1) 0.94 BALF galactomannan, ODI 3.7 (2.9–4.5) 3.6 (2.6–4.6) 0.94 Microbiology Aspergillus species 39 (23.4) 18 (19.8) 0.53 A. fumigatus 21 14 - A. flavus 18 4 - Underlying etiology for CPA 0.35 Tuberculosis 129 (86) 65 (81.3) Nontuberculosis 21 (14) 15 (18.7) CT thorax findings Number of cavities 1.8 (1.7–2) 1.8 (1.6–2) 0.70 Presence of fungal balls 93 (62) 55 (68.8) 0.39 Fungal balls 0.9 (0.8–1) 0.82 (0.7–1) 0.48 Category of CPA 0.82 Simple aspergilloma 13 (8.7) 7 (8.8) CCPA 112 (74.7) 63 (78.8) CFPA 25 (16.7) 10 (12.5) Severe CPA 79 (52.7) 37 (46.3) 0.41 All values are represented as a mean (95% confidence intervals) or number (percentage), unless stated; BALF: bronchoalveolar lavage fluid; BMI: body mass index; CCPA: chronic cavitary pulmonary aspergillosis; CFPA: chronic fibrosing pulmonary aspergillosis; CPA: chronic pulmonary aspergillosis; CRP: C–reactive protein; CT: computed tomography; ESR: erythrocyte sedimentation rate; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; ODI: optical density index; SGRQ: St George’s respiratory questionnaire. ==== Refs References 1. Denning D.W. Riniotis K. Dobrashian R. Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: Case series, proposed nomenclature change, and review Clin. Infect. Dis. 2003 37 Suppl. 3 S265 S280 10.1086/376526 12975754 2. Sehgal I.S. Dhooria S. Muthu V. Prasad K.T. Agarwal R. An overview of the available treatments for chronic cavitary pulmonary aspergillosis Expert Rev. Respir. Med. 2020 14 715 727 10.1080/17476348.2020.1750956 32249630 3. Denning D.W. Cadranel J. Beigelman-Aubry C. Ader F. Chakrabarti A. Blot S. Ullmann A.J. Dimopoulos G. Lange C. Chronic pulmonary aspergillosis: Rationale and clinical guidelines for diagnosis and management Eur. Respir. J. 2016 47 45 68 10.1183/13993003.00583-2015 26699723 4. Bongomin F. Harris C. Foden P. Kosmidis C. Denning D.W. Innate and Adaptive Immune Defects in Chronic Pulmonary Aspergillosis J. Fungi 2017 3 26 10.3390/jof3020026 5. Harrison E. Singh A. Morris J. Smith N.L. Fraczek M.G. Moore C.B. Denning D.W. Mannose-binding lectin genotype and serum levels in patients with chronic and allergic pulmonary aspergillosis Int. J. Immunogenet. 2012 39 224 232 10.1111/j.1744-313X.2011.01078.x 22225939 6. Wang F. Zhang C. Jiang Y. Kou C. Kong Q. Long N. Lu L. Sang H. Innate and adaptive immune response to chronic pulmonary infection of hyphae of Aspergillus fumigatus in a new murine model J. Med. Microbiol. 2017 66 1400 1408 10.1099/jmm.0.000590 28923131 7. Hewison M. An update on vitamin D and human immunity Clin. Endocrinol. 2012 76 315 325 10.1111/j.1365-2265.2011.04261.x 8. Herr C. Greulich T. Koczulla R.A. Meyer S. Zakharkina T. Branscheidt M. Eschmann R. Bals R. The role of vitamin D in pulmonary disease: COPD, asthma, infection, and cancer Respir. Res. 2011 12 31 10.1186/1465-9921-12-31 21418564 9. Agarwal R. Sehgal I.S. Dhooria S. Aggarwal A.N. Sachdeva N. Bhadada S.K. Garg M. Behera D. Chakrabarti A. Vitamin D levels in asthmatic patients with and without allergic bronchopulmonary aspergillosis Mycoses 2018 61 344 349 10.1111/myc.12744 29314357 10. White J.H. Vitamin D signaling, infectious diseases, and regulation of innate immunity Infect. Immun. 2008 76 3837 3843 10.1128/IAI.00353-08 18505808 11. Sehgal I.S. Dhooria S. Choudhary H. Aggarwal A.N. Garg M. Chakrabarti A. Agarwal R. Efficiency of A fumigatus-specific IgG and galactomannan testing in the diagnosis of simple aspergilloma Mycoses 2019 62 1108 1115 10.1111/myc.12987 31408547 12. Sehgal I.S. Dhooria S. Choudhary H. Aggarwal A.N. Garg M. Chakrabarti A. Agarwal R. Utility of Serum and Bronchoalveolar Lavage Fluid Galactomannan in Diagnosis of Chronic Pulmonary Aspergillosis J. Clin. Microbiol. 2019 57 10.1128/JCM.01821-18 30626661 13. Denning D.W. Page I.D. Chakaya J. Jabeen K. Jude C.M. Cornet M. Alastruey-Izquierdo A. Bongomin F. Bowyer P. Chakrabarti A. Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings Emerg. Infect. Dis. 2018 24 e171312 10.3201/eid2408.171312 30016256 14. Al-Shair K. Atherton G.T.W. Kennedy D. Powell G. Denning D.W. Caress A. Validity and reliability of the St. George’s Respiratory Questionnaire in assessing health status in patients with chronic pulmonary aspergillosis Chest 2013 144 623 631 10.1378/chest.12-0014 23188518 15. Sehgal I.S. Choudhary H. Dhooria S. Aggarwal A.N. Garg M. Chakrabarti A. Agarwal R. Diagnostic cut-off of Aspergillus fumigatus -specific IgG in the diagnosis of chronic pulmonary aspergillosis Mycoses 2018 61 770 776 10.1111/myc.12815 29920796 16. Agarwal R. Aggarwal A.N. Sehgal I.S. Dhooria S. Behera D. Chakrabarti A. Utility of IgE (total and Aspergillus fumigatus specific) in monitoring for response and exacerbations in allergic bronchopulmonary aspergillosis Mycoses 2016 59 1 6 10.1111/myc.12423 26575791 17. Dodamani M.H. Muthu V. Thakur R. Pal A. Sehgal I.S. Dhooria S. Aggarwal A.N. Garg M. Chakrabarti A. Agarwal R. A randomised trial of vitamin D in acute-stage allergic bronchopulmonary aspergillosis complicating asthma Mycoses 2019 62 320 327 10.1111/myc.12879 30561849 18. Ok M. Einsele H. Loeffler J. Genetic susceptibility to Aspergillus fumigatus infections Int. J. Med. Microbiol. 2011 301 445 452 10.1016/j.ijmm.2011.04.013 21550849 19. Sirivoranankul C. Martinez M. Chen V. Clemons K.V. Stevens D.A. Vitamin D and experimental invasive aspergillosis Med. Mycol. 2014 52 847 852 10.1093/mmy/myu048 25231772 20. Hu S. Dai J. Chen X. Vitamin D reduces autophagy by regulating NF-κB resistance to Aspergillus fumigatus infection Gene 2020 753 144819 10.1016/j.gene.2020.144819 32485309 21. Boonstra A. Barrat F.J. Crain C. Heath V.L. Savelkoul H.F. O’Garra A. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells J. Immunol. 2001 167 4974 4980 10.4049/jimmunol.167.9.4974 11673504 22. Prietl B. Treiber G. Pieber T.R. Amrein K. Vitamin D and immune function Nutrients 2013 5 2502 2521 10.3390/nu5072502 23857223 23. Chishimba L. Zhang W. Andrew Mochridge A.M. Niven R.M. Al-Shar K. Denning D. Vitamin D deficiency in asthma patients with allergic bronchopulmonary aspergillosis (ABPA) Eur. Respir. J. 2013 42 P4178 24. Kearns M.D. Tangpricha V. The role of vitamin D in tuberculosis J. Clin. Transl. Endocrinol. 2014 1 167 169 10.1016/j.jcte.2014.08.002 29159097 25. Ustianowski A. Shaffer R. Collin S. Wilkinson R.J. Davidson R.N. Prevalence and associations of vitamin D deficiency in foreign-born persons with tuberculosis in London J. Infect. 2005 50 432 437 10.1016/j.jinf.2004.07.006 15907552 26. Gupta R. Gupta A. Vitamin D deficiency in India: Prevalence, causalities and interventions Nutrients 2014 6 729 775 10.3390/nu6020729 24566435